Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008, Zhengzhou, China Jiangxue Hou, Yufu Li & Quande Lin Authors 1. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting Jiangxue Hou1, Yufu Li1 & Quande Lin 1 Experimental Hematology & Oncology volume 12, Article number: 86 (2023) Cite this article 110 Accesses Metrics details The Original Article was published on 26 August 2023 Experimental Hematology & Oncology (2023) 12:74 https://doi.org/10.1186/s40164-023-00436-9 After online publication of the article1, the authors noticed Table 1 and 2 should have been published in the main article were inadvertently submitted and processed as Supplementary files.